Drug Search Results
More Filters [+]

Asunaprevir

Alternative Names: asunaprevir, bms-650032, sunvepra
Latest Update: 2023-08-22
Latest Update Note: PubMed Publication

Product Description

Asunaprevir is an orally bioavailable inhibitor of the nonstructural protein 3 (NS3), with potential activity against hepatitis C virus (HCV).  (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Asunaprevir)

Mechanisms of Action: HCV-NS3/4A Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Canada | Chile | Colombia | Japan | Korea | New Zealand | Peru | Russia | Taiwan | Turkey

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Asunaprevir

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Kidney Failure, Chronic|Hepatitis A|Hepatitis C, Chronic

Phase 3: Hepatitis C, Chronic|Hepatitis C|Hepatitis A

Phase 2: Hepatitis C, Chronic|Liver Transplant|Coinfection|Hepatitis C|HIV Infections|Hepatitis A|Communicable Diseases

Phase 1: Hepatitis C|Hepatic Insufficiency|Liver Failure

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

C-DIAMOND

N/A

Unknown status

Hepatitis C, Chronic|Hepatitis A

2021-07-31

RELIF-C

N/A

Unknown status

Hepatitis A|Hepatitis C, Chronic|Liver Cirrhosis

2018-12-01

AI447-118

P4

Completed

Kidney Failure, Chronic|Hepatitis C, Chronic

2018-04-01

DARING

P3

Completed

Hepatitis C

2018-04-01

Recent News Events